Given that the immunomodulatory effect mediated by CD39-expressing T cells is strongly associated with treatment response in RA, therapies targeting the CD39/ADO pathway in T cells may improve RA treatments. This evidence concerns the gene ENTPD1 and rheumatoid arthritis.